Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

URL of this page:


What is it?

Resveratrol is a chemical mostly found in red grapes and products made from these grapes (wine, juice). It may be helpful for hay fever and weight loss.

Resveratrol might have many effects in the body, including expanding blood vessels and reducing blood clotting. It may also decrease pain and swelling, reduce levels of sugar in the blood, and help the body fight against disease.

Resveratrol is most commonly used for high cholesterol, cancer, heart disease, and many other conditions. But there is no strong evidence to support resveratrol for any use.

How effective is it?

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for RESVERATROL are as follows:

Possibly effective for...

  • Hay fever. Using a nasal spray containing resveratrol three times daily for 4 weeks seems to reduce allergy symptoms in adults with seasonal allergies. Using a nasal spray containing resveratrol and beta-glucans three times daily for 2 months also seems to reduce allergy symptoms in children with seasonal allergies.
  • Obesity. Taking resveratrol by mouth seems to increase weight loss in overweight and obese adults. But it doesn't seem to improve blood pressure, glucose control, or levels of cholesterol and other fats.

Possibly ineffective for...

  • Heart disease. People who consume higher amounts of dietary resveratrol do not seem to have a lower risk of heart disease compared to people who consume lower amounts. Also, taking resveratrol by mouth does not seem to improve levels of cholesterol or blood fats called triglycerides in people at risk for heart disease.
  • High cholesterol. Taking resveratrol by mouth does not seem to improve levels of cholesterol or blood fats called triglycerides.
  • A grouping of symptoms that increase the risk of diabetes, heart disease, and stroke (metabolic syndrome). Taking resveratrol by mouth doesn't seem to lower blood pressure, blood sugar, or cholesterol in people with metabolic syndrome.
  • Build up of fat in the liver in people who drink little or no alcohol (nonalcoholic fatty liver disease or NAFLD). Taking resveratrol by mouth doesn't seem to improve liver function, liver scarring, or cholesterol levels in people with NAFLD.
There is interest in using resveratrol for a number of other purposes, but there isn't enough reliable information to say whether it might be helpful.

Is it safe?

When taken by mouth: People often consume resveratrol in small amounts in foods. Resveratrol supplements are possibly safe when taken by mouth in doses up to 1500 mg daily for up to 3 months. Higher doses of up to 2000-3000 mg daily have been used safely for 2-6 months. But these higher doses are more likely to cause stomach upset.

When applied to the skin: Resveratrol is possibly safe when used for up to 30 days.
When sprayed into the nose: Resveratrol is possibly safe when used for up to 4 weeks.

Special precautions & warnings:

Pregnancy and breast-feeding: Resveratrol is likely safe when used in amounts found in some foods. However, during pregnancy and breast-feeding, the source of resveratrol is important. Resveratrol is found in grape skins, grape juice, wine, and other food sources. Wine should not be used as a source of resveratrol when pregnant or breast-feeding.

Children: People often consume resveratrol in small amounts in foods. But there isn't enough reliable information to know if it safe to take by mouth in larger amounts. Resveratrol is possibly safe in children when sprayed in the nose for up to 2 months.

Bleeding disorders: Resveratrol might slow blood clotting and increase the risk of bleeding in people with bleeding disorders.

Hormone-sensitive condition such as breast cancer, uterine cancer, ovarian cancer, endometriosis, or uterine fibroids: Resveratrol might act like estrogen. If you have any condition that might be made worse by exposure to estrogen, don't use resveratrol.

Surgery: Resveratrol might increase the risk of bleeding during and after surgery. Stop using resveratrol at least 2 weeks before a scheduled surgery.

Are there interactions with medications?

Be cautious with this combination.
Medications changed by the liver (Cytochrome P450 1A1 (CYP1A1) substrates)
Some medications are changed and broken down by the liver. Resveratrol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates)
Some medications are changed and broken down by the liver. Resveratrol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 1B1 (CYP1B1) substrates)
Some medications are changed and broken down by the liver. Resveratrol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates)
Some medications are changed and broken down by the liver. Resveratrol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2E1 (CYP2E1) substrates)
Some medications are changed and broken down by the liver. Resveratrol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates)
Some medications are changed and broken down by the liver. Resveratrol might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications that slow blood clotting (Anticoagulant / Antiplatelet drugs)
Resveratrol might slow blood clotting. Taking resveratrol along with medications that also slow blood clotting might increase the risk of bruising and bleeding.

Are there interactions with herbs and supplements?

Herbs and supplements that might slow blood clotting
Resveratrol might slow blood clotting and increase the risk of bleeding. Taking it with other supplements with similar effects might increase the risk of bleeding in some people. Examples of supplements with this effect include garlic, ginger, ginkgo, nattokinase, and Panax ginseng.

Are there interactions with foods?

Resveratrol can be taken with or without food. But taking resveratrol with fatty foods might reduce how much the body absorbs.

How is it typically used?

Resveratrol has most often been used by adults in doses of 250-1000 mg by mouth daily for up to 3 months. It is also sometimes used in nasal sprays. Speak with a healthcare provider to find out what dose might be best for a specific condition.

Other names

3,5,4' TriHydroxy-Transstibene, (E)- 5-(4-hydroxystyryl)benzene-1,3-diol, 3,4',5-stilbenetriol, 3,5,4' -trihydroxystilbene, 3,4',5-trihydroxystilbene, 3,5,4'-trihydroxy-trans-stilbene, Cis-Resveratrol, Extrait de Vin, Extrait de Vin Rouge, Kojo-Kon, Phytoalexin, Phytoalexine, Phytoestrogen, Phyto-œstrogène, Pilule de Vin, Protykin, Red Wine Extract, Resvératrol, Resveratrols, Resvératrols, RSV, RSVL, Stilbene Phytoalexin, Trans-Resveratrol, Trans-Resvératrol, Wine Extract, Wine Pill.


To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.


  1. Gonçalinho GHF, Kuwabara KL, Faria NFO, et al. Sirtuin 1 and Vascular Function in Healthy Women and Men: A Randomized Clinical Trial Comparing the Effects of Energy Restriction and Resveratrol. Nutrients. 2023 Jun 29;15:2949. View abstract.
  2. Ali Fadlalmola H, Elhusein AM, Al-Sayaghi KM, et al. Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. Pan Afr Med J. 2023 Mar 16;44:134. View abstract.
  3. Corbi G, Nobile V, Conti V, et al. Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial. Int J Mol Sci. 2023 Jul 27;24:12063. View abstract.
  4. Scaturro D, Vitagliani F, Tomasello S, Sconza C, Respizzi S, Letizia Mauro G. Combined Rehabilitation with Alpha Lipoic Acid, Acetyl-L-Carnitine, Resveratrol, and Cholecalciferolin Discogenic Sciatica in Young People: A Randomized Clinical Trial. Medicina (Kaunas) 2023;59:2197. View abstract.
  5. Fatima S, Khan DA, Aamir M, Pervez MA, Fatima F. d-Tocotrienol in Combination with Resveratrol Improves the Cardiometabolic Risk Factors and Biomarkers in Patients with Metabolic Syndrome: A Randomized Controlled Trial. Metab Syndr Relat Disord 2023;21:25-34. View abstract.
  6. Abdollahi S, Vajdi M, Meshkini F, et al. Resveratrol may mildly improve renal function in the general adult population: A systematic review and meta-analysis of randomized controlled clinical trials. Nutr Res 2023;113:1-13. View abstract.
  7. Nikniaz S, Vaziri F, Mansouri R. Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trail. BMC Oral Health 2023;23:177. View abstract.
  8. Badaoui A. Allergic contact dermatitis to resveratrol and Scutellaria baicalensis root extract in a cosmetic product. Contact Dermatitis 2022. View abstract.
  9. Cao X, Liao W, Xia H, Wang S, Sun G. The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials. Nutrients 2022;14:3755. View abstract.
  10. Gorabi AM, Aslani S, Imani D, Razi B, Sathyapalan T, Sahebkar A. Effect of resveratrol on C-reactive protein: An updated meta-analysis of randomized controlled trials. Phytother Res 2021;35:6754-6767. View abstract.
  11. Gu W, Geng J, Zhao H, Li X, Song G. Effects of resveratrol on metabolic indicators in patients with type 2 diabetes: A systematic review and meta-analysis. Int J Clin Pract 2022;2022:9734738. View abstract.
  12. Ali Sangouni A, Abdollahi S, Mozaffari-Khosravi H. Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial. BMC Cardiovasc Disord 2022;22:212. View abstract.
  13. Teimouri M, Homayouni-Tabrizi M, Rajabian A, Amiri H, Hosseini H. Anti-inflammatory effects of resveratrol in patients with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med 2022;70:102863. View abstract.
  14. Abdelhaleem IA, Brakat AM, Adayel HM, Asla MM, Rizk MA, Aboalfetoh AY. The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: A systematic review and meta-analysis. Med Clin (Barc) 2022;158:576-585. View abstract.
  15. Dzator JSA, Howe PRC, Coupland KG, Wong RHX. A randomised, double-blind, placebo-controlled crossover trial of resveratrol supplementation for prophylaxis of hormonal migraine. Nutrients 2022;14:1763. View abstract.
  16. García-Martínez BI, Ruiz-Ramos M, Pedraza-Chaverri J, Santiago-Osorio E, Mendoza-Núñez VM. Influence of age and dose on the effect of resveratrol for glycemic control in type 2 diabetes mellitus: Systematic review and meta-analysis. Molecules 2022;27:5232. View abstract.
  17. McCreary MR, Schnell PM, Rhoda DA. Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19). Sci Rep 2022;12:10978. View abstract.
  18. Li Q, Yang G, Xu H, Tang S, Lee WY. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complement Med Ther 2021;21:214. View abstract.
  19. Løkken N, Khawajazada T, Storgaard JH, et al. No effect of resveratrol in patients with mitochondrial myopathy: A cross-over randomized controlled trial. J Inherit Metab Dis 2021;44:1186-1198. View abstract.
  20. Mansour A, Samadi M, Sanginabadi M, et al. Effect of resveratrol on menstrual cyclicity, hyperandrogenism and metabolic profile in women with PCOS. Clin Nutr 2021;40:4106-4112. View abstract.
  21. Rafiee S, Mohammadi H, Ghavami A, Sadeghi E, Safari Z, Askari G. Efficacy of resveratrol supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. Complement Ther Clin Pract. 2021;42:101281. View abstract.
  22. de Ligt M, Bergman M, Fuentes RM, et al. No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial. Am J Clin Nutr. 2020;112:1029-1038. View abstract.
  23. Hosseini H, Koushki M, Khodabandehloo H, et al. The effect of resveratrol supplementation on C-reactive protein (CRP) in type 2 diabetic patients: Results from a systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 2020;49:102251. View abstract.
  24. Akbari M, Tamtaji OR, Lankarani KB, et al. The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis. 2020;19:25. View abstract.
  25. Akbari M, Tamtaji OR, Lankarani KB, et al. The effects of resveratrol supplementation on endothelial function and blood pressures among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. High Blood Press Cardiovasc Prev 2019;26:305-19. View abstract.
  26. Köbe T, Witte AV, Schnelle A, et al. Impact of resveratrol on glucose control, hippocampal structure and connectivity, and memory performance in patients with mild cognitive impairment. Front Neurosci 2017;11:105. View abstract.
  27. Witte AV, Kerti L, Margulies DS, Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci 2014;34:7862-70. View abstract.
  28. Mousavi SM, Milajerdi A, Sheikhi A, et al. Resveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials. Obes Rev 2019;20:487-98. View abstract.
  29. Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B, Omrani GR, Shams M. Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double-blind placebo-controlled clinical trial. Diabetes Metab 2019;45:53-9. View abstract.
  30. Zhang C, Yuan W, Fang J, Wang W, He P, Lei J, Wang C. Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials. PLoS One. 2016 Aug 25;11:e0161792. View abstract.
  31. Poulsen MK, Nellemann B, Bibby BM, et al. No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. Diabetes Obes Metab. 2018;20:2504-2509. View abstract.
  32. Hussain SA, Marouf BH, Ali ZS, Ahmmad RS. Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study. Clin Interv Aging. 2018;13:1621-1630. View abstract.
  33. Huhn S, Beyer F, Zhang R, et al. Effects of resveratrol on memory performance, hippocampus connectivity and microstructure in older adults - A randomized controlled trial. Neuroimage. 2018;174:177-190. View abstract.
  34. Haghpanah S, Zarei T, Eshghi P, et al. Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia. Ann Hematol. 2018;97:1919-1924. View abstract.
  35. Anton SD, Ebner N, Dzierzewski JM, et al. Effects of 90 Days of Resveratrol Supplementation on Cognitive Function in Elders: A Pilot Study. J Altern Complement Med. 2018;24:725-732. View abstract.
  36. Lv C, Zhang Y, Shen L. Preliminary clinical effect evaluation of resveratrol in adults with allergic rhinitis. Int Arch Allergy Immunol 2018;175:231-6. View abstract.
  37. Zortea K, Franco VC, Francesconi LP, Cereser KM, Lobato MI, Belmonte-de-Abreu PS. Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors. Nutrients. 2016;8:73. View abstract.
  38. Wightman EL, Haskell-Ramsay CF, Reay JL, et al. The effects of chronic trans-resveratrol supplementation on aspects of cognitive function, mood, sleep, health and cerebral blood flow in healthy, young humans. Br J Nutr. 2015;114:1427-37. View abstract.
  39. Turner RS, Thomas RG, Craft S, et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015;85:1383-91. View abstract.
  40. Timmers S, de Ligt M, Phielix E, et al. Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 2016;39:2211-2217. View abstract.
  41. Samsami-Kor M, Daryani NE, Asl PR, Hekmatdoost A. Anti-Inflammatory Effects of Resveratrol in Patients with Ulcerative Colitis: A Randomized, Double-Blind, Placebo-controlled Pilot Study. Arch Med Res. 2015;46:280-5. View abstract.
  42. Lin CT, Sun XY, Lin AX. Supplementation with high-dose trans-resveratrol improves ultrafiltration in peritoneal dialysis patients: a prospective, randomized, double-blind study. Ren Fail. 2016;38:214-21. View abstract.
  43. Kjaer TN, Ornstrup MJ, Poulsen MM, et al. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men. Prostate. 2015;75:1255-63. View abstract.
  44. Kjaer TN, Ornstrup MJ, Poulsen MM, et al. No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial. J Clin Endocrinol Metab. 2017;102:1642-1651. View abstract.
  45. Evans HM, Howe PR, Wong RH. Effects of Resveratrol on Cognitive Performance, Mood and Cerebrovascular Function in Post-Menopausal Women; A 14-Week Randomised Placebo-Controlled Intervention Trial. Nutrients. 2017;9. View abstract.
  46. Elgebaly A, Radwan IA, AboElnas MM, et al. Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-analysis. J Gastrointestin Liver Dis. 2017;26:59-67. View abstract.
  47. Bo S, Ponzo V, Ciccone G, et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol Res. 2016;111:896-905. View abstract.
  48. Bedada SK, Neerati P. Resveratrol Pretreatment Affects CYP2E1 Activity of Chlorzoxazone in Healthy Human Volunteers. Phytother Res. 2016;30:463-8. View abstract.
  49. Banaszewska B, Wrotynska-Barczynska J, Spaczynski RZ, Pawelczyk L, Duleba AJ. Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial. J Clin Endocrinol Metab. 2016;101:4322-4328. View abstract.
  50. Khojah HM, Ahmed S, Abdel-Rahman MS, Elhakeim EH. Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study. Clin Rheumatol. 2018;[Epub ahead of print]. View abstract.
  51. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012 May 2;15:675-90. View abstract.
  52. Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R, Bapat P, Kwun I, Shen CL. Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014 Jan;25:1-18. View abstract.
  53. Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cozzolino F, Ciriolo MR, Garaci E. Inhibition of influenza A virus replication by resveratrol. J Infect Dis. 2005 May 15;191:1719-29. View abstract.
  54. Mastromarino P, Capobianco D, Cannata F, Nardis C, Mattia E, De Leo A, Restignoli R, Francioso A, Mosca L. Resveratrol inhibits rhinovirus replication and expression of inflammatory mediators in nasal epithelia. Antiviral Res. 2015 Nov;123:15-21. View abstract.
  55. Semba RD, Ferrucci L, Bartali B, Urpí-Sarda M, Zamora-Ros R, Sun K, Cherubini A, Bandinelli S, Andres-Lacueva C. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med. 2014 Jul;174:1077-84. View abstract.
  56. Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2013 Dec;71:822-35. View abstract.
  57. Miraglia Del Giudice M, Maiello N, Capristo C, Alterio E, Capasso M, Perrone L, Ciprandi G. Resveratrol plus carboxymethyl-ß-glucan reduces nasal symptoms in children with pollen-induced allergic rhinitis. Curr Med Res Opin. 2014 Oct;30:1931-5. View abstract.
  58. Méndez-del Villar M, González-Ortiz M, Martínez-Abundis E, Pérez-Rubio KG, Lizárraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014 Dec;12:497-501. View abstract.
  59. Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, Battyany I, Sumegi B, Toth K, Szabados E. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50:179-87. View abstract.
  60. Liu K, Zhou R, Wang B, Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2014 Jun;99:1510-9. View abstract.
  61. Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014 Oct;34:837-43. View abstract.
  62. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12:2092-103.e1-6. View abstract.
  63. Hudson, G. M., Shelmadine, B., Cooke, M., Genovese, J., Greenwood, M., and Willoughby, D. S. Resveratrol Supplementation And Changes In Glucose, Insulin, And mRNA Expression Following Exercise In Overweight Females: 2467. Medicine & Science in Sports & Exercise 2011;43
  64. Guarnieri, R., Pappacoda, A., and Solitro, S. [A resveratrol containing compound reduces oxidative stress and ameliorates clinical symptoms in COPD subjects] Un composto a base di resveratrolo riduce lo stress ossidativo e migliora la sintomatologia clinica in soggetti con BPCO. Cochrane Central Register of Controlled Trials 2009;
  65. Yoon, S. J., Cho, K. S., Lee, Y. H., Kim, D. S., and Hong, S. J. RESVERATROL INHIBITS CXCR4 MEDIATED TUMOR GROWTH AND MIGRATION OF HUMAN KIDNEY CANCER CELL IN VITRO AND IN VIVO: 428. Journal of Urology 2009;181:153-154.
  66. Klink, J. C., Poulton, S., Antonelli, J., Potter, M. Q., Jayachandran, J., Tewari, A. K., Febbo, P. G., Pizzo, S. V., and Freedland, S. RESVERATROL ALTERS PROSTATE CANCER XENOGRAFT GROWTH: 724. Journal of Urology 2009;181
  67. Seely, K. A. Cannabinoid receptor inverse agonists as novel therapeutic agents." The Sciences and Engineering. The Sciences and Engineering 2009;70(4-B)
  68. Pregliasco, F. and Cogo, R. [Antioxidant and immunomodulating compounds in older people undergoing seasonal influenza vaccination improve serological response and reduce tract respiratory episodes] L'uso di sostanze antiossidanti ed immunomodulanti in una popolazione anziana so. Cochrane Central Register of Controlled Trials 2010;
  69. Steigerwald, M. D., Fisk, M. Z., Smoliga, J. M., and Rundell, K. W. Effects Of Resveratrol On Oxidative Stress And Vascular Function Following Exercise In Simulated Air Pollution: 2645. Medicine & Science in Sports & Exercise 2011;43
  70. Bost, J., Smoliga, J. M., Bost, K. M., and Maroon, J. C. Three Months Oral Supplementation of a Unique Polyphenol Mixture Improves Physical and Neurocognitive Performance Indicators in Sedentary Adults: 2205. Medicine & Science in Sports & Exercise 2008;40:S246.
  71. Grujic Milanovic, J., Mihailovic-Stanojevic, N., Miloradovic, Z., Jacevic, V., Milosavljevic, I., Milanovic, S., Ivanov, M., and Jovovic, D. J. RESVERATROL REDUCES BLOOD PRESSURE, CHANGES OF ANTIOXIDANT ENZYME ACTIVITY AND HISTOLOGICAL PARAMETERS IN EXPERIMENTAL MODEL OF MALIGNANT HYPERTENSION PP.29.171. Journal of Hypertension 2010;28
  72. Pendurthi, U. R., Williams, J. T., and Rao, L. V. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells : A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler.Thromb.Vasc.Biol 1999;19:419-426. View abstract.
  73. Rotondo, S., Rajtar, G., Manarini, S., Celardo, A., Rotillo, D., de Gaetano, G., Evangelista, V., and Cerletti, C. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br.J.Pharmacol. 1998;123:1691-1699. View abstract.
  74. Bhatt, J. K., Thomas, S., and Nanjan, M. J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr.Res. 2012;32:537-541. View abstract.
  75. Hector, K. L., Lagisz, M., and Nakagawa, S. The effect of resveratrol on longevity across species: a meta-analysis. Biol.Lett. 10-23-2012;8:790-793. View abstract.
  76. Roehr, B. Cardiovascular researcher fabricated data in studies of red wine. BMJ 2012;344:e406. View abstract.
  77. Crandall, J. P., Oram, V., Trandafirescu, G., Reid, M., Kishore, P., Hawkins, M., Cohen, H. W., and Barzilai, N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J.Gerontol.A Biol.Sci.Med.Sci. 2012;67:1307-1312. View abstract.
  78. Fujitaka, K., Otani, H., Jo, F., Jo, H., Nomura, E., Iwasaki, M., Nishikawa, M., Iwasaka, T., and Das, D. K. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr.Res 2011;31:842-847. View abstract.
  79. Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., Moonen-Kornips, E., Hesselink, M. K., Kunz, I., Schrauwen-Hinderling, V. B., Blaak, E. E., Auwerx, J., and Schrauwen, P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 11-2-2011;14:612-622. View abstract.
  80. Xuzhu, G., Komai-Koma, M., Leung, B. P., Howe, H. S., McSharry, C., McInnes, I. B., and Xu, D. Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function. Ann.Rheum.Dis 2012;71:129-135. View abstract.
  81. Knight, C. M., Gutierrez-Juarez, R., Lam, T. K., Arrieta-Cruz, I., Huang, L., Schwartz, G., Barzilai, N., and Rossetti, L. Mediobasal hypothalamic SIRT1 is essential for resveratrol's effects on insulin action in rats. Diabetes 2011;60:2691-2700. View abstract.
  82. Howells, L. M., Berry, D. P., Elliott, P. J., Jacobson, E. W., Hoffmann, E., Hegarty, B., Brown, K., Steward, W. P., and Gescher, A. J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev.Res (Phila) 2011;4:1419-1425. View abstract.
  83. Wuertz, K., Quero, L., Sekiguchi, M., Klawitter, M., Nerlich, A., Konno, S., Kikuchi, S., and Boos, N. The red wine polyphenol resveratrol shows promising potential for the treatment of nucleus pulposus-mediated pain in vitro and in vivo. Spine (Phila Pa 1976.) 10-1-2011;36:E1373-E1384. View abstract.
  84. Brasnyo, P., Molnar, G. A., Mohas, M., Marko, L., Laczy, B., Cseh, J., Mikolas, E., Szijarto, I. A., Merei, A., Halmai, R., Meszaros, L. G., Sumegi, B., and Wittmann, I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106:383-389. View abstract.
  85. Fabbrocini, G., Staibano, S., De, Rosa G., Battimiello, V., Fardella, N., Ilardi, G., La Rotonda, M. I., Longobardi, A., Mazzella, M., Siano, M., Pastore, F., De, Vita, V, Vecchione, M. L., and Ayala, F. Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind, vehicle-controlled, pilot study. Am J Clin.Dermatol 4-1-2011;12:133-141. View abstract.
  86. Kitada, M., Kume, S., Imaizumi, N., and Koya, D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 2011;60:634-643. View abstract.
  87. Shindler, K. S., Ventura, E., Dutt, M., Elliott, P., Fitzgerald, D. C., and Rostami, A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol. 2010;30:328-339. View abstract.
  88. Brown, V. A., Patel, K. R., Viskaduraki, M., Crowell, J. A., Perloff, M., Booth, T. D., Vasilinin, G., Sen, A., Schinas, A. M., Piccirilli, G., Brown, K., Steward, W. P., Gescher, A. J., and Brenner, D. E. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 11-15-2010;70:9003-9011. View abstract.
  89. Patel, K. R., Brown, V. A., Jones, D. J., Britton, R. G., Hemingway, D., Miller, A. S., West, K. P., Booth, T. D., Perloff, M., Crowell, J. A., Brenner, D. E., Steward, W. P., Gescher, A. J., and Brown, K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 10-1-2010;70:7392-7399. View abstract.
  90. Knobloch, J., Sibbing, B., Jungck, D., Lin, Y., Urban, K., Stoelben, E., Strauch, J., and Koch, A. Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol.Exp.Ther 2010;335:788-798. View abstract.
  91. Wong, R. H., Howe, P. R., Buckley, J. D., Coates, A. M., Kunz, I., and Berry, N. M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr.Metab Cardiovasc.Dis 2011;21:851-856. View abstract.
  92. la, Porte C., Voduc, N., Zhang, G., Seguin, I., Tardiff, D., Singhal, N., and Cameron, D. W. Steady-State pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin.Pharmacokinet. 2010;49:449-454. View abstract.
  93. Le Couteur, D. G. and Sinclair, D. A. A blueprint for developing therapeutic approaches that increase healthspan and delay death. J Gerontol.A Biol.Sci.Med Sci. 2010;65:693-694. View abstract.
  94. Kennedy, D. O., Wightman, E. L., Reay, J. L., Lietz, G., Okello, E. J., Wilde, A., and Haskell, C. F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin.Nutr. 2010;91:1590-1597. View abstract.
  95. Daffner, K. R. Promoting successful cognitive aging: a comprehensive review. J Alzheimers.Dis 2010;19:1101-1122. View abstract.
  96. Yu, H. P., Hwang, T. L., Hwang, T. L., Yen, C. H., and Lau, Y. T. Resveratrol prevents endothelial dysfunction and aortic superoxide production after trauma hemorrhage through estrogen receptor-dependent hemeoxygenase-1 pathway. Crit Care Med 2010;38:1147-1154. View abstract.
  97. Albani, D., Polito, L., and Forloni, G. Sirtuins as novel targets for Alzheimer's disease and other neurodegenerative disorders: experimental and genetic evidence. J Alzheimers.Dis 2010;19:11-26. View abstract.
  98. Guo, J. P., Yu, S., and McGeer, P. L. Simple in vitro assays to identify amyloid-beta aggregation blockers for Alzheimer's disease therapy. J Alzheimers.Dis. 2010;19:1359-1370. View abstract.
  99. Jha, R. K., Ma, Q., Sha, H., and Palikhe, M. Protective effect of resveratrol in severe acute pancreatitis-induced brain injury. Pancreas 2009;38:947-953. View abstract.
  100. Zhang, H., Zhang, J., Ungvari, Z., and Zhang, C. Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler.Thromb.Vasc.Biol. 2009;29:1164-1171. View abstract.
  101. Bournival, J., Quessy, P., and Martinoli, M. G. Protective effects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol.Neurobiol. 2009;29:1169-1180. View abstract.
  102. Almeida, L., Vaz-da-Silva, M., Falcao, A., Soares, E., Costa, R., Loureiro, A. I., Fernandes-Lopes, C., Rocha, J. F., Nunes, T., Wright, L., and Soares-da-Silva, P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol.Nutr.Food Res 2009;53 Suppl 1:S7-15. View abstract.
  103. Vingtdeux, V., Dreses-Werringloer, U., Zhao, H., Davies, P., and Marambaud, P. Therapeutic potential of resveratrol in Alzheimer's disease. BMC.Neurosci. 2008;9 Suppl 2:S6. View abstract.
  104. Fan, E., Zhang, L., Jiang, S., and Bai, Y. Beneficial effects of resveratrol on atherosclerosis. J Med Food 2008;11:610-614. View abstract.
  105. Vaz-da-Silva, M., Loureiro, A. I., Falcao, A., Nunes, T., Rocha, J. F., Fernandes-Lopes, C., Soares, E., Wright, L., Almeida, L., and Soares-da-Silva, P. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int.J Clin.Pharmacol.Ther 2008;46:564-570. View abstract.
  106. Orallo, F. Trans-resveratrol: a magical elixir of eternal youth? Curr.Med Chem. 2008;15:1887-1898. View abstract.
  107. Rocha-Gonzalez, H. I., Ambriz-Tututi, M., and Granados-Soto, V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS.Neurosci.Ther 2008;14:234-247. View abstract.
  108. Calabrese, V., Cornelius, C., Mancuso, C., Pennisi, G., Calafato, S., Bellia, F., Bates, T. E., Giuffrida Stella, A. M., Schapira, T., Dinkova Kostova, A. T., and Rizzarelli, E. Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem.Res 2008;33:2444-2471. View abstract.
  109. Pearson, K. J., Baur, J. A., Lewis, K. N., Peshkin, L., Price, N. L., Labinskyy, N., Swindell, W. R., Kamara, D., Minor, R. K., Perez, E., Jamieson, H. A., Zhang, Y., Dunn, S. R., Sharma, K., Pleshko, N., Woollett, L. A., Csiszar, A., Ikeno, Y., Le Couteur, D., Elliott, P. J., Becker, K. G., Navas, P., Ingram, D. K., Wolf, N. S., Ungvari, Z., Sinclair, D. A., and de Cabo, R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008;8:157-168. View abstract.
  110. Dong, W., Li, N., Gao, D., Zhen, H., Zhang, X., and Li, F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J Vasc.Surg. 2008;48:709-714. View abstract.
  111. Yu, H. P., Hsu, J. C., Hwang, T. L., Yen, C. H., and Lau, Y. T. Resveratrol attenuates hepatic injury after trauma-hemorrhage via estrogen receptor-related pathway. Shock 2008;30:324-328. View abstract.
  112. Bass, T. M., Weinkove, D., Houthoofd, K., Gems, D., and Partridge, L. Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech.Ageing Dev 2007;128:546-552. View abstract.
  113. Gruber, J., Tang, S. Y., and Halliwell, B. Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann N Y.Acad Sci 2007;1100:530-542. View abstract.
  114. Baur, J. A. and Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493-506. View abstract.
  115. Valenzano, D. R., Terzibasi, E., Genade, T., Cattaneo, A., Domenici, L., and Cellerino, A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr Biol 2-7-2006;16:296-300. View abstract.
  116. Rakici, O., Kiziltepe, U., Coskun, B., Aslamaci, S., and Akar, F. Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int.J Cardiol 11-2-2005;105:209-215. View abstract.
  117. Ma, Z. H. and Ma, Q. Y. Resveratrol: a medical drug for acute pancreatitis. World J Gastroenterol. 6-7-2005;11:3171-3174. View abstract.
  118. Molnar, V. and Garai, J. Plant-derived anti-inflammatory compounds affect MIF tautomerase activity. Int.Immunopharmacol. 2005;5:849-856. View abstract.
  119. Provinciali, M., Re, F., Donnini, A., Orlando, F., Bartozzi, B., Di Stasio, G., and Smorlesi, A. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int.J Cancer 5-20-2005;115:36-45. View abstract.
  120. Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., and Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24(5A):2783-2840. View abstract.
  121. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr., and Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32:1377-1382. View abstract.
  122. Jannin, B., Menzel, M., Berlot, J. P., Delmas, D., Lancon, A., and Latruffe, N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem.Pharmacol. 9-15-2004;68:1113-1118. View abstract.
  123. Evers, D. L., Wang, X., Huong, S. M., Huang, D. Y., and Huang, E. S. 3,4',5-Trihydroxy-trans-stilbene (resveratrol) inhibits human cytomegalovirus replication and virus-induced cellular signaling. Antiviral Res. 2004;63:85-95. View abstract.
  124. Piver, B., Fer, M., Vitrac, X., Merillon, J. M., Dreano, Y., Berthou, F., and Lucas, D. Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochem.Pharmacol. 8-15-2004;68:773-782. View abstract.
  125. Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., and Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 8-5-2004;430:686-689. View abstract.
  126. Olas, B., Wachowicz, B., Bald, E., and Glowacki, R. The protective effects of resveratrol against changes in blood platelet thiols induced by platinum compounds. J.Physiol Pharmacol. 2004;55:467-476. View abstract.
  127. Cavallaro, A., Ainis, T., Bottari, C., and Fimiani, V. Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol Res. 2003;52:555-562. View abstract.
  128. Kim, Y. A., Lee, W. H., Choi, T. H., Rhee, S. H., Park, K. Y., and Choi, Y. H. Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int.J.Oncol. 2003;23:1143-1149. View abstract.
  129. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L. L., Scherer, B., and Sinclair, D. A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 9-11-2003;425:191-196. View abstract.
  130. Delmas, D., Rebe, C., Lacour, S., Filomenko, R., Athias, A., Gambert, P., Cherkaoui-Malki, M., Jannin, B., Dubrez-Daloz, L., Latruffe, N., and Solary, E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J.Biol.Chem. 10-17-2003;278:41482-41490. View abstract.
  131. Liang, Y. C., Tsai, S. H., Chen, L., Lin-Shiau, S. Y., and Lin, J. K. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem.Pharmacol. 4-1-2003;65:1053-1060. View abstract.
  132. Klinge, C. M., Risinger, K. E., Watts, M. B., Beck, V., Eder, R., and Jungbauer, A. Estrogenic activity in white and red wine extracts. J Agric.Food Chem 3-26-2003;51:1850-1857. View abstract.
  133. Vitrac, X., Desmouliere, A., Brouillaud, B., Krisa, S., Deffieux, G., Barthe, N., Rosenbaum, J., and Merillon, J. M. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 4-4-2003;72:2219-2233. View abstract.
  134. Levenson, A. S., Gehm, B. D., Pearce, S. T., Horiguchi, J., Simons, L. A., Ward, J. E., III, Jameson, J. L., and Jordan, V. C. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int.J.Cancer 5-1-2003;104:587-596. View abstract.
  135. Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M., and van Breemen, R. B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun.Mass Spectrom. 2003;17:307-313. View abstract.
  136. Olas, B., Wachowicz, B., Saluk-Juszczak, J., and Zielinski, T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb.Res 8-15-2002;107(3-4):141-145. View abstract.
  137. Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H., Witte, K., and Forstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 9-24-2002;106:1652-1658. View abstract.
  138. Sharma, M. and Gupta, Y. K. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 10-11-2002;71:2489-2498. View abstract.
  139. Holian, O., Wahid, S., Atten, M. J., and Attar, B. M. Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. Am.J.Physiol Gastrointest.Liver Physiol 2002;282:G809-G816. View abstract.
  140. Potter, G. A., Patterson, L. H., Wanogho, E., Perry, P. J., Butler, P. C., Ijaz, T., Ruparelia, K. C., Lamb, J. H., Farmer, P. B., Stanley, L. A., and Burke, M. D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br.J.Cancer 3-4-2002;86:774-778. View abstract.
  141. Falchetti, R., Fuggetta, M. P., Lanzilli, G., Tricarico, M., and Ravagnan, G. Effects of resveratrol on human immune cell function. Life Sci. 11-21-2001;70:81-96. View abstract.
  142. Bhavnani, B. R., Cecutti, A., Gerulath, A., Woolever, A. C., and Berco, M. Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause. 2001;8:408-419. View abstract.
  143. Bhat, K. P., Lantvit, D., Christov, K., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 10-15-2001;61:7456-7463. View abstract.
  144. Lee, J. E. and Safe, S. Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem.Pharmacol. 10-15-2001;62:1113-1124. View abstract.
  145. Bhat, K. P. and Pezzuto, J. M. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res. 8-15-2001;61:6137-6144. View abstract.
  146. Nicolini, G., Rigolio, R., Miloso, M., Bertelli, A. A., and Tredici, G. Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neurosci.Lett. 4-13-2001;302:41-44. View abstract.
  147. Giovannini, L., Migliori, M., Longoni, B. M., Das, D. K., Bertelli, A. A., Panichi, V., Filippi, C., and Bertelli, A. Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. J Cardiovasc.Pharmacol. 2001;37:262-270. View abstract.
  148. Wang, M. J., Huang, H. M., Hsieh, S. J., Jeng, K. C., and Kuo, J. S. Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol. 1-1-2001;112(1-2):28-34. View abstract.
  149. Chang, T. K., Lee, W. B., and Ko, H. H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can.J.Physiol Pharmacol. 2000;78:874-881. View abstract.
  150. Burkitt, M. J. and Duncan, J. Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action. Arch.Biochem.Biophys. 9-15-2000;381:253-263. View abstract.
  151. Zbikowska, H. M. and Olas, B. Antioxidants with carcinostatic activity (resveratrol, vitamin E and selenium) in modulation of blood platelet adhesion. J Physiol Pharmacol. 2000;51:513-520. View abstract.
  152. Kirk, R. I., Deitch, J. A., Wu, J. M., and Lerea, K. M. Resveratrol decreases early signaling events in washed platelets but has little effect on platalet in whole food. Blood Cells Mol.Dis. 2000;26:144-150. View abstract.
  153. Bagchi, D., Bagchi, M., Stohs, S. J., Das, D. K., Ray, S. D., Kuszynski, C. A., Joshi, S. S., and Pruess, H. G. Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology 8-7-2000;148(2-3):187-197. View abstract.
  154. Bradamante, S., Piccinini, F., Barenghi, L., Bertelli, A. A., De Jonge, R., Beemster, P., and De Jong, J. W. Does resveratrol induce pharmacological preconditioning? Int.J Tissue React. 2000;22:1-4. View abstract.
  155. Naderali, E. K., Doyle, P. J., and Williams, G. Resveratrol induces vasorelaxation of mesenteric and uterine arteries from female guinea-pigs. Clin Sci (Lond) 2000;98:537-543. View abstract.
  156. Klabunde, T., Petrassi, H. M., Oza, V. B., Raman, P., Kelly, J. W., and Sacchettini, J. C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat Struct.Biol. 2000;7:312-321. View abstract.
  157. Martinez, J. and Moreno, J. J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem.Pharmacol 4-1-2000;59:865-870. View abstract.
  158. Subbaramaiah, K., Michaluart, P., Chung, W. J., Tanabe, T., Telang, N., and Dannenberg, A. J. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann.N.Y.Acad.Sci. 1999;889:214-223. View abstract.
  159. Dobrydneva, Y., Williams, R. L., and Blackmore, P. F. trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br.J.Pharmacol. 1999;128:149-157. View abstract.
  160. Ciolino, H. P. and Yeh, G. C. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol.Pharmacol. 1999;56:760-767. View abstract.
  161. Lin, J. K. and Tsai, S. H. Chemoprevention of cancer and cardiovascular disease by resveratrol. Proc.Natl.Sci.Counc.Repub.China B 1999;23:99-106. View abstract.
  162. Zou, J. G., Huang, Y. Z., Chen, Q., Wei, E. H., Hsieh, T. C., and Wu, J. M. Resveratrol inhibits copper ion-induced and azo compound-initiated oxidative modification of human low density lipoprotein. Biochem.Mol.Biol.Int. 1999;47:1089-1096. View abstract.
  163. Rahman, I. Antioxidant therapeutic advances in COPD. Ther.Adv.Respir.Dis. 2008;2:351-374. View abstract.
  164. Kimura, Y., Okuda, H., and Kubo, M. Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes. J Ethnopharmacol. 1995;45:131-139. View abstract.
  165. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Garcia-Almagro, F. J., Aviles-Plaza, F., Parra, S., Yanez-Gascon, M. J., Ruiz-Ros, J. A., Garcia-Conesa, M. T., Tomas-Barberan, F. A., and Espin, J. C. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol.Nutr Food Res 2012;56:810-821. View abstract.
  166. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M. J., Garcia-Almagro, F. J., Ruiz-Ros, J. A., Garcia-Conesa, M. T., Tomas-Barberan, F. A., and Espin, J. C. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 8-1-2012;110:356-363. View abstract.
  167. Zern, T. L., Wood, R. J., Greene, C., West, K. L., Liu, Y., Aggarwal, D., Shachter, N. S., and Fernandez, M. L. Grape polyphenols exert a cardioprotective effect in pre- and postmenopausal women by lowering plasma lipids and reducing oxidative stress. J Nutr. 2005;135:1911-1917. View abstract.
  168. de, Santi C., Pietrabissa, A., Mosca, F., and Pacifici, G. M. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 2000;30:1047-1054. View abstract.
  169. Rosa, F. T., Zulet, M. A., Marchini, J. S., and Martinez, J. A. Bioactive compounds with effects on inflammation markers in humans. Int J Food Sci Nutr 2012;63:749-765. View abstract.
  170. Chang, T. K., Chen, J., and Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J.Pharmacol.Exp.Ther. 2001;299:874-882. View abstract.
  171. Basly, J. P., Marre-Fournier, F., Le Bail, J. C., Habrioux, G., and Chulia, A. J. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci. 1-21-2000;66:769-777. View abstract.
  172. Mueller SO, Simon S, Chae K, et al. Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells. Toxicol Sci 2004;80:14-25. View abstract.
  173. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16:1246-52. View abstract.
  174. Lyons MM, Yu C, Toma RB, et al. Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem 2003;51:5867-70. View abstract.
  175. Trincheri NF, Nicotra G, Follo C, et al. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis 2007;28:922-31. View abstract.
  176. Scarlatti F, Sala G, Somenzi G, et al. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 2003;17:2339-41. View abstract.
  177. Wang Q, Li H, Wang XW, et al. Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci Lett 2003;351:83-6. View abstract.
  178. Culpitt SV, Rogers DF, Fenwick PS, et al. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003;58:942-6. View abstract.
  179. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003;17:1975-85. View abstract.
  180. Savaskan E, Olivieri G, Meier F, et al. Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontology 2003;49:380-3. View abstract.
  181. Gao X, Deeb D, Media J, et al. Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem Pharmacol 2003;66:2427-35. View abstract.
  182. Schriever C, Pendland SL, Mahady GB. Red wine, resveratrol, Chlamydia pneumoniae and the French connection. Atherosclerosis 2003;171:379-80. View abstract.
  183. Ziegler CC, Rainwater L, Whelan J, McEntee MF. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J Nutr 2004;134:5-10. View abstract.
  184. Kim YA, Choi BT, Lee YT, et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep 2004;11:441-6. View abstract.
  185. Zhang Y, Jayaprakasam B, Seeram NP, et al. Insulin secretion and cyclooxygenase enzyme inhibition by cabernet sauvignon grape skin compounds. J Agric Food Chem 2004;52:228-33. View abstract.
  186. Opipari AW Jr, Tan L, Boitano AE, et al. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004;64:696-703. View abstract.
  187. Abou-Zeid LA, El-Mowafy AM. Differential recognition of resveratrol isomers by the human estrogen receptor-alpha: molecular dynamics evidence for stereoselective ligand binding. Chirality 2004;16:190-5. View abstract.
  188. Meng X, Maliakal P, Lu H, et al. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004;52:935-42. View abstract.
  189. Hascalik S, Celik O, Turkoz Y, et al. Resveratrol, a red wine constituent polyphenol, protects from ischemia-reperfusion damage of the ovaries. Gynecol Obstet Invest 2004;57:218-23. View abstract.
  190. Ahmad KA, Clement MV, Hanif IM, Pervaiz S. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 2004;64:1452-9. View abstract.
  191. Li W, Seifert M, Xu Y, Hock B. Comparative study of estrogenic potencies of estradiol, tamoxifen, bisphenol-A and resveratrol with two in vitro bioassays. Environ Int 2004;30:329-35. View abstract.
  192. Martin AR, Villegas I, La Casa C, de la Lastra CA. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem Pharmacol 2004;67:1399-410. View abstract.
  193. Szewczuk LM, Forti L, Stivala LA, Penning TM. Resveratrol is a peroxidase mediated inactivator of COX-1 but not COX-2: A mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004;279:22727-37. View abstract.
  194. Wang Z, Huang Y, Zou J, et al. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int J Mol Med 2002;9:77-9. View abstract.
  195. Mokni M, Limam F, Elkahoui S, et al. Strong cardioprotective effect of resveratrol, a red wine polyphenol, on isolated rat hearts after ischemia/reperfusion injury. Arch Biochem Biophys 2007;457:1-6. View abstract.
  196. Elmali N, Baysal O, Harma A, et al. Effects of resveratrol in inflammatory arthritis. Inflammation 2007;30:1-6. View abstract.
  197. Bujanda L, Garcia-Barcina M, Gutierrez-de Juan V, et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol 2006;6:35. View abstract.
  198. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-42. View abstract.
  199. Murias M, Handler N, Erker T, et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 2004;12:5571-8. View abstract.
  200. Hwang D, Fischer NH, Jang BC, et al. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 1996;226:810-8.. View abstract.
  201. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23:9247-58. View abstract.
  202. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003;36:79-87.. View abstract.
  203. Docherty JJ, Fu MM, Stiffler BS, et al. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 1999;43:145-55. View abstract.
  204. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000;141:3657-67.
  205. Piver B, Berthou F, Dreano Y, Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 2001;125:83-91. View abstract.
  206. Laden BP, Porter TD. Resveratrol inhibits human squalene monooxygenase. Nutr Res 2001;21:747-53.
  207. Kozuki Y, Miura Y, Yagasaki K. Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action.Cancer Lett 2001;167:151-6. View abstract.
  208. Schneider Y, Vincent F, Duranton B, et al. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 2000;158:85-91.
  209. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19:2739-45. View abstract.
  210. Holmes-McNary M, Baldwin AS, Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000;60:3477-83. View abstract.
  211. Bertelli AA, Giovannini L, Giannessi D, et al. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 1995;17:1-3. View abstract.
  212. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci U S A 1997;94:14138-43. View abstract.
  213. Carbo N, Costelli P, Baccino FM, et al. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 1999;254:739-43. View abstract.
  214. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999;20:237-42. View abstract.
  215. Davy BM, Melby CL, Beske SD, et al. Oat consumption does not affect resting casual and ambulatory 24-h arterial blood pressure in men with high-normal blood pressure to stage I hypertension. J Nutr 2002;132:394-8.. View abstract.
  216. Chen CK, Pace-Asciak CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 1996;27:363-6. View abstract.
  217. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998;24:133-8. View abstract.
  218. Pace-Asciak CR, Hahn S, Diamandis EP, et al. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995;235:207-19. View abstract.
  219. Bertelli AA, Giovannini L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22:61-3. View abstract.
  220. Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246:163-82. View abstract.
  221. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20. View abstract.
  222. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997;30:91-113. View abstract.
  223. Agri Res Svc: Dr. Duke's phytochemical and ethnobotanical databases. (Accessed 3 November 1999).
  224. The Review of Natural Products by Facts and Comparisons. St. Louis, MO: Wolters Kluwer Co., 1999.
  225. Foster S, Tyler VE. Tyler's Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. 3rd ed., Binghamton, NY: Haworth Herbal Press, 1993.
  226. Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professionals. London, UK: The Pharmaceutical Press, 1996.
  227. Tyler VE. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press, 1994.
  228. Blumenthal M, ed. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Trans. S. Klein. Boston, MA: American Botanical Council, 1998.
  229. Monographs on the medicinal uses of plant drugs. Exeter, UK: European Scientific Co-op Phytother, 1997.
Last reviewed - 02/23/2024